Published in Nat Protoc on October 17, 2013
Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat Genet (2014) 2.11
Targeting renal cell carcinoma with a HIF-2 antagonist. Nature (2016) 1.68
Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing. Nat Protoc (2014) 0.90
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation. J Immunother Cancer (2016) 0.79
An integrative somatic mutation analysis to identify pathways linked with survival outcomes across 19 cancer types. Bioinformatics (2015) 0.78
Delayed effects of developmental exposure to low levels of the aryl hydrocarbon receptor agonist 3,3',4,4',5-pentachlorobiphenyl (PCB126) on adult zebrafish behavior. Neurotoxicology (2015) 0.77
Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma. Mol Cell Biol (2016) 0.76
Unique epigenetic gene profiles define human breast cancers with poor prognosis. Oncotarget (2016) 0.75
Methods and compositions for amplification and detection of microRNAs (miRNAs) and noncoding RNAs (ncRNAs) using the signature sequence amplification method (SSAM). Recent Adv DNA Gene Seq (2014) 0.75
Single-Cell mRNA Sequencing in Cancer Research: Integrating the Genomic Fingerprint. Front Genet (2017) 0.75
Modeling Renal Cell Carcinoma in mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade. Cancer Discov (2017) 0.75
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
Rapid and simple method for purification of nucleic acids. J Clin Microbiol (1990) 44.73
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13
Isolation of high-molecular-weight DNA from mammalian cells. Eur J Biochem (1973) 24.38
Tumour evolution inferred by single-cell sequencing. Nature (2011) 19.13
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet (2011) 14.29
Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 13.60
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques (1993) 9.61
Non-coding RNA genes and the modern RNA world. Nat Rev Genet (2001) 9.06
PIWI-interacting small RNAs: the vanguard of genome defence. Nat Rev Mol Cell Biol (2011) 5.59
The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat Protoc (2006) 5.41
BAP1 loss defines a new class of renal cell carcinoma. Nat Genet (2012) 4.97
Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet (2013) 4.61
Improved northern blot method for enhanced detection of small RNA. Nat Protoc (2008) 4.47
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res (2008) 4.02
Laser-capture microdissection. Nat Protoc (2006) 3.80
Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet (2011) 3.66
DNA methylation: bisulphite modification and analysis. Nat Protoc (2006) 3.44
Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res (1995) 3.33
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol (2012) 3.20
Regulation of TFEB and V-ATPases by mTORC1. EMBO J (2011) 2.84
Genome-wide copy number analysis of single cells. Nat Protoc (2012) 2.47
MicroRNA expression profiling using microarrays. Nat Protoc (2008) 2.44
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res (2013) 2.26
A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med (2012) 1.84
Methylome analysis using MeDIP-seq with low DNA concentrations. Nat Protoc (2012) 1.70
Southern blotting. Nat Protoc (2006) 1.68
Quantitative proteome analysis using isotope-coded affinity tags and mass spectrometry. Nat Protoc (2006) 1.61
Cancer genome-sequencing study design. Nat Rev Genet (2013) 1.55
From human genome to cancer genome: the first decade. Genome Res (2013) 1.42
Rapid in situ codetection of noncoding RNAs and proteins in cells and formalin-fixed paraffin-embedded tissue sections without protease treatment. Nat Protoc (2010) 1.41
Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Mol Cancer Res (2011) 1.33
Northern blot analysis for detection and quantification of RNA in pancreatic cancer cells and tissues. Nat Protoc (2009) 1.23
Defining transcribed regions using RNA-seq. Nat Protoc (2010) 1.17
Preparation of genomic DNA from mammalian tissue. Curr Protoc Mol Biol (2001) 1.17
Structural analysis and functional implications of the negative mTORC1 regulator REDD1. Biochemistry (2010) 1.04
Cooperation and antagonism among cancer genes: the renal cancer paradigm. Cancer Res (2013) 1.04
State-of-the-art two-dimensional gel electrophoresis: a key tool of proteomics research. Nat Protoc (2006) 0.96
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
BAP1 loss defines a new class of renal cell carcinoma. Nat Genet (2012) 4.97
Regulation of TFEB and V-ATPases by mTORC1. EMBO J (2011) 2.84
The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol (2011) 2.72
Renal-cell carcinoma--molecular pathways and therapies. N Engl J Med (2007) 2.06
A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med (2012) 1.84
Trex1 regulates lysosomal biogenesis and interferon-independent activation of antiviral genes. Nat Immunol (2012) 1.83
Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol (2012) 1.75
State of the science: an update on renal cell carcinoma. Mol Cancer Res (2012) 1.58
Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer (2013) 1.36
Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Mol Cancer Res (2011) 1.33
Succination of Keap1 and activation of Nrf2-dependent antioxidant pathways in FH-deficient papillary renal cell carcinoma type 2. Cancer Cell (2011) 1.12
Sirolimus and temsirolimus for epithelioid angiomyolipoma. J Clin Oncol (2010) 1.10
Chemical inhibition of RNA viruses reveals REDD1 as a host defense factor. Nat Chem Biol (2011) 1.04
Structural analysis and functional implications of the negative mTORC1 regulator REDD1. Biochemistry (2010) 1.04
Cooperation and antagonism among cancer genes: the renal cancer paradigm. Cancer Res (2013) 1.04
Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1. Hum Mol Genet (2009) 1.03
Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC. Nat Rev Urol (2011) 0.98
Cell-type-dependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia. Mol Cell Biol (2011) 0.95
TFEB, a novel mTORC1 effector implicated in lysosome biogenesis, endocytosis and autophagy. Cell Cycle (2011) 0.90
Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months. J Clin Oncol (2013) 0.90
Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib. J Clin Oncol (2013) 0.81
Platelet-derived growth factor/vascular endothelial growth factor receptor inactivation by sunitinib results in Tsc1/Tsc2-dependent inhibition of TORC1. Mol Cell Biol (2013) 0.78
mTORC1 activation in childhood ependymoma and response to sirolimus. J Neurooncol (2010) 0.76
Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus. Cancer Biol Ther (2015) 0.75
Predictive Biomarkers for Molecularly Targeted Therapies in Renal Cell Carcinoma. J Natl Compr Canc Netw (2016) 0.75